Taysha Gene Therapies, Inc.

TSHA Nasdaq CIK: 0001806310

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247
Mailing Address 3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247
Phone (214) 612-0000
Fiscal Year End 1231
EIN 843199512

Financial Overview

FY2024 FY

$15.45M
Revenue
$88.84M
Total Liabilities
$143.94M
Cash & Equivalents
$-0.36
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report February 6, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 5, 2026 View on SEC
4 Insider stock transaction report January 27, 2026 View on SEC
4 Insider stock transaction report January 27, 2026 View on SEC
4 Insider stock transaction report January 27, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment January 21, 2026 View on SEC
4 Insider stock transaction report January 14, 2026 View on SEC
4 Insider stock transaction report January 14, 2026 View on SEC
4 Insider stock transaction report January 14, 2026 View on SEC
4 Insider stock transaction report December 1, 2025 View on SEC

Insider Trading

STRONG SELL 3 insiders 10 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.